• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 10th May 2016

New publication: The current and future burden of late-onset dementia in the UK: estimates and interventions

A new publication, based on research conducted by OHE, suggests that by 2025 the disability adjusted life year (DALY) burden of dementia will have increased by 42% from the Global Disease Burden (GDB) 2010 estimate. A new publication, based on…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new publication, based on research conducted by OHE, suggests that by 2025 the disability adjusted life year (DALY) burden of dementia will have increased by 42% from the Global Disease Burden (GDB) 2010 estimate.

A new publication, based on research conducted by OHE, suggests that by 2025 the disability adjusted life year (DALY) burden of dementia will have increased by 42% from the Global Disease Burden (GDB) 2010 estimate.

The risk of developing dementia increases markedly with age, and with the global population – both developed and developing countries – ageing rapidly, dementia has the potential to be a major future health concern.

The new study, published in Alzheimers and Dementia, aimed to estimate the burden of late-onset dementia in the United Kingdom through to 2025, and to quantitatively assess the impact of three potential interventions. The interventions considered, all of which were assumed to commence is 2018, were:

  1. an optimistic limiting case of a 100% preventive intervention with immediate uptake of 100% of the population at risk;
  2. an intervention which delays onset by five years, linear uptake to 50% after five years;
  3. as ii) but uptake 75% after five years.

The authors assume that prevalence is fixed at recent estimates, and measure the burden in DALYs, allowing them to be compared with those in the GDB 2010 estimates (Horton 2012; Murray et al., 2013).

For 2015 the authors estimate a burden of approximately 440K (i.e. 440,000) DALYs. For 2020 and 2025 the numbers are 494K and 551K DALYs respectively. This means that by 2025 the DALY burden will have increased by 42% from the Global Disease Burden (GDB) 2010 estimate of 387K DALYs.

Intervention results:

  1. a 9% decrease by 2025;
  2. a 33% increase; and
  3. a 28% increase.    

The authors conclude that: “At current prevalence rates, the ability of an intervention to offset the projected increase in DALY burden of dementia in the UK by 2025 appears low”.

Dr Matthew Norton, Head of Policy at Alzheimer’s Research UK, said: “Currently there is no cure for dementia and with cases of the condition set to rise to over one million in the UK by 2025, it’s one of the greatest social and economic challenges of our time. Although this study shows that even with a new treatment, we may still see a rise in the number of years of life lost to ill health from dementia by 2025, such a treatment could help ease the devastating personal impact the condition has on those diagnosed, their loved ones and carers. The more research is carried out, the better we can understand the diseases underlying dementia and work towards a treatment to slow down or stop their progression. Research is the only way to defeat dementia and ease the personal, social and economic impact of this cruel condition.”

Read the full paper here.

Access related OHE work below:

Lewis, F., 2015. Estimation of Future Cases of Dementia from Those Born in 2015. OHE Consulting Report. London: Office of Health Economics.

Marsden, G. & Mestre-Ferrandiz, J., 2015. Dementia: the R&D Landscape. OHE Research Report. London: Office of Health Economics.

Lewis, F., Karlsberg Schaffer, S., Sussex, J., O’Neill, P. and Cockcroft, L., 2014. The trajectory of dementia in the UK – making a difference. OHE Consulting Report. London: Office of Health Economics.

References:

Horton, R., 2010. GBD 2010: understanding disease, injury, and risk. Lancet, 380, pp. 2053–4.

Murray, C., Richards, M., Newton, J., Fenton, K., Anderson, H., Atkinson, C., et al., 2013. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet, 381, pp. 997–1020.

  • Health Data and Statistics
  • Economics of Innovation
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!